Cure8 trial brief
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose disease has not responded to existing therapies.
Adults with moderately to severely active ulcerative colitis; patients who have failed or are intolerant of conventional or advanced therapies; gastroenterologists and researchers in IBD clinical trials.
A Phase 2 interventional trial (NCT06598943) is recruiting adults with moderately to severely active ulcerative colitis to evaluate the safety and efficacy of eltrekibart and mirikizumab given alone or in combination.
Planned enrollment is about 140 participants with primary outcomes including percentage achieving clinical remission at Week 12; total participation is roughly 69 weeks. The study includes arms for eltrekibart plus placebo, mirikizumab plus placebo, combination eltrekibart + mirikizumab, and placebo.
Eligibility requires prior inadequate response or intolerance to conventional or advanced UC therapies and excludes prior anti-IL-23p19 or anti-IL-12p40 exposure. This summary is based on the ClinicalTrials.gov record (trial registration) and describes the registered trial design and eligibility; it does not report results.
This is a Phase 2, recruiting clinical trial record from ClinicalTrials.gov sponsored by Eli Lilly and Company. The entry describes planned trial design and endpoints but does not provide results. Mirikizumab is an anti–IL-23p19 biologic; eltrekibart is investigational. Participation requires meeting specific inclusion/exclusion criteria listed on the registry.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...
Combining a UC biologic (mirikizumab) with a weight-loss drug (tirzepatide) could address both intestinal inflammation and excess weight, which may be important for people with moderately to severely active ulcerative...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
